IL1B and cryopyrin-associated periodic syndrome: Canakinumab, a fully human monoclonal antibody against IL-1β (Figure 2b), has shown promising clinical efficacy and safety in various inflammatory diseases like cryopyrin-associated periodic syndromes (CAPS) and possibly other complex inflammatory diseases, such as rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis (SoJIA), chronic obstructive pulmonary disease, and ocular diseases [30].